nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

07.11.2015 | Original Paper

First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia

verfasst von: Kjetil N. Jørgensen, Ragnar Nesvåg, Sindre Gunleiksrud, Andrea Raballo, Erik G. Jönsson, Ingrid Agartz

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Antipsychotic medication may influence brain structure, but to what extent effects of first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) differ is still not clear. Here we aimed to disentangle the effects of FGA and SGA on variation in volumes of subcortical structures in patients with long-term treated schizophrenia. Magnetic resonance images were obtained from 95 patients with schizophrenia and 106 healthy control subjects. Among the patients, 40 received only FGA and 42 received only SGA. FreeSurfer 5.3.0 was used to obtain volumes of 27 subcortical structures as well as total brain volume and estimated intracranial volume. Findings of reduced total brain volume, enlarged ventricular volume and reduced hippocampal volume bilaterally among patients were replicated, largely independent of medication class. In the basal ganglia, FGA users had larger putamen bilaterally and right caudate volume compared to healthy controls, and the right putamen was significantly larger than among SGA users. FGA and SGA users had similar and larger globus pallidus volumes compared to healthy controls. Post hoc analyses revealed that the difference between FGA and SGA could be attributed to smaller volumes in the clozapine users specifically. We therefore conclude that basal ganglia volume enlargements are not specific to FGA.

Nur mit Berechtigung zugänglich

Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005) The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 30(9):1649–1661. doi:10.1038/sj.npp.1300710 CrossRefPubMed

Vernon AC, Natesan S, Modo M, Kapur S (2011) Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 69(10):936–944. doi:10.1016/j.biopsych.2010.11.010 CrossRefPubMed

Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011) Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68(2):128–137. doi:10.1001/archgenpsychiatry.2010.199 CrossRefPubMedPubMedCentral

Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC (1998) Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 155(12):1711–1717. doi:10.1176/ajp.155.12.1711 CrossRefPubMed

Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M (1994) Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 151(10):1430–1436. doi:10.1176/ajp.151.10.1430 CrossRefPubMed

Chakos MH, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga CA (1998) Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 44(8):675–684. doi:10.1016/S0006-3223(98)00029-8 CrossRefPubMed

Brandt GN, Bonelli RM (2008) Structural neuroimaging of the basal ganglia in schizophrenic patients: a review. Wien Med Wochenschr 158(3–4):84–90. doi:10.1007/s10354-007-0478-7 CrossRefPubMed

Ballmaier M, Schlagenhauf F, Toga AW, Gallinat J, Koslowski M, Zoli M, Hojatkashani C, Narr KL, Heinz A (2008) Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophr Res 106(2–3):140–147. doi:10.1016/j.schres.2008.08.025 CrossRefPubMedPubMedCentral

Boonstra G, van Haren NE, Schnack HG, Cahn W, Burger H, Boersma M, de Kroon B, Grobbee DE, Hulshoff Pol HE HE, Kahn RS (2011) Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J Clin Psychopharmacol 31(2):146–153. doi:10.1097/JCP.0b013e31820e3f58 CrossRefPubMed

10.

Li M, Chen Z, Deng W, He Z, Wang Q, Jiang L, Ma X, Wang Y, Chua SE, Cheung C, McAlonan GM, Sham PC, Collier DA, Gong Q, Li T (2012) Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. Psychol Med 42(7):1475–1483. doi:10.1017/S0033291711002157 CrossRefPubMed

11.

Navari S, Dazzan P (2009) Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med 39(11):1763–1777. doi:10.1017/S0033291709005315 CrossRefPubMed

12.

Chua SE, Deng Y, Chen EY, Law CW, Chiu CP, Cheung C, Wong JC, Lienenkaemper N, Cheung V, Suckling J, McAlonan GM (2009) Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. Psychol Med 39(5):793–800. doi:10.1017/S0033291708004212 CrossRefPubMed

13.

Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS (2001) The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 24(1):47–54CrossRefPubMed

14.

Scherk H, Falkai P (2006) Effects of antipsychotics on brain structure. Curr Opin Psychiatry 19(2):145–150. doi:10.1097/01.yco.0000214339.06507.d8 CrossRefPubMed

15.

Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC (1999) Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 156(8):1200–1204PubMed

16.

Ebdrup BH, Norbak H, Borgwardt S, Glenthoj B (2013) Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr Med Chem 20(3):438–447. doi:10.2174/0929867311320030015 PubMedPubMedCentral

17.

Lewis S, Lieberman J (2008) CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 192(3):161–163. doi:10.1192/bjp.bp.107.037218 CrossRefPubMed

18.

Gjerden P, Slordal L, Bramness JG (2009) Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol 65(12):1229–1235CrossRefPubMed

19.

Stahl SM (2013) Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, vol 4. Cambridge University Press, Cambridge

20.

Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519–526CrossRefPubMed

21.

Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393–406. doi:10.1146/annurev-med-050911-161504 CrossRefPubMed

22.

Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31(9):1991–2001. doi:10.1038/sj.npp.1301108 CrossRefPubMed

23.

Nelson AB, Kreitzer AC (2014) Reassessing models of basal ganglia function and dysfunction. Annu Rev Neurosci 37:117–135. doi:10.1146/annurev-neuro-071013-013916 CrossRefPubMedPubMedCentral

24.

Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM (2005) Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP Study. Neuropsychopharmacology 30(4):765–774. doi:10.1038/sj.npp.1300603 PubMed

25.

Smith MJ, Wang L, Cronenwett W, Mamah D, Barch DM, Csernansky JG (2011) Thalamic morphology in schizophrenia and schizoaffective disorder. J Psychiatr Res 45(3):378–385. doi:10.1016/j.jpsychires.2010.08.003 CrossRefPubMed

26.

Deicken RF, Eliaz Y, Chosiad L, Feiwell R, Rogers L (2002) Magnetic resonance imaging of the thalamus in male patients with schizophrenia. Schizophr Res 58(2–3):135–144. doi:10.1016/S0920-9964(01)00330-9 CrossRefPubMed

27.

Shenton ME, Dickey CC, Frumin M, McCarley RW (2001) A review of MRI findings in schizophrenia. Schizophr Res 49(1–2):1–52. doi:10.1016/S0920-9964(01)00163-3 CrossRefPubMedPubMedCentral

28.

Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA (2006) Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 188:510–518. doi:10.1192/bjp.188.6.510 CrossRefPubMed

29.

Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB, Lublin H, Skimminge A, Baare W (2010) Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci 35(2):95–104. doi:10.1503/jpn.090049 CrossRefPubMedPubMedCentral

30.

Szeszko PR, Goldberg E, Gunduz-Bruce H, Ashtari M, Robinson D, Malhotra AK, Lencz T, Bates J, Crandall DT, Kane JM, Bilder RM (2003) Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry 160(12):2190–2197. doi:10.1176/appi.ajp.160.12.2190 CrossRefPubMed

31.

Ebdrup BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, Lublin H, Baare W, Glenthoj B (2011) Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int J Neuropsychopharmacol 14(1):69–82. doi:10.1017/S1461145710000817 CrossRefPubMed

32.

Koolschijn PC, van Haren NE, Cahn W, Schnack HG, Janssen J, Klumpers F, Hulshoff Pol HE, Kahn RS (2010) Hippocampal volume change in schizophrenia. J Clin Psychiatry 71(6):737–744CrossRefPubMed

33.

Irle E, Lange C, Ruhleder M, Exner C, Siemerkus J, Weniger G (2011) Hippocampal size in women but not men with schizophrenia relates to disorder duration. Psychiatry Res 192(3):133–139. doi:10.1016/j.pscychresns.2010.12.009 CrossRefPubMed

34.

Nesvag R, Lawyer G, Varnas K, Fjell AM, Walhovd KB, Frigessi A, Jonsson EG, Agartz I (2008) Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. Schizophr Res 98(1–3):16–28. doi:10.1016/j.schres.2007.09.015 CrossRefPubMed

35.

Nesvag R, Frigessi A, Jonsson EG, Agartz I (2007) Effects of alcohol consumption and antipsychotic medication on brain morphology in schizophrenia. Schizophr Res 90(1–3):52–61. doi:10.1016/j.schres.2006.11.008 CrossRefPubMed

36.

Tamagaki C, Sedvall GC, Jonsson EG, Okugawa G, Hall H, Pauli S, Agartz I (2005) Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. Am J Psychiatry 162(12):2315–2321. doi:10.1176/appi.ajp.162.12.2315 CrossRefPubMed

37.

Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45(9):789–796CrossRefPubMed

38.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163(4):600–610. doi:10.1176/appi.ajp.163.4.600 CrossRefPubMed

39.

Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32(4):715–723. doi:10.1093/schbul/sbj067 CrossRefPubMedPubMedCentral

40.

Frazier JA, Giedd JN, Kaysen D, Albus K, Hamburger S, Alaghband-Rad J, Lenane MC, McKenna K, Breier A, Rapoport JL (1996) Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry 153(4):564–566CrossRefPubMed

41.

Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M (1995) Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 345(8947):456–457CrossRefPubMed

42.

Spitzer RL, Williams JBV, Gibbon M, First MB (1988) Structured clinical interview for the DSM-III-R—patient version (SCID-P). Biometrics Research Department, New York State Psychiatric Institute, New York

43.

Jonsson EG, Edman-Ahlbom B, Sillen A, Gunnar A, Kulle B, Frigessi A, Vares M, Ekholm B, Wode-Helgodt B, Schumacher J, Cichon S, Agartz I, Sedvall GC, Hall H, Terenius L (2006) Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog Neuropsychopharmacol Biol Psychiatry 30(5):924–933. doi:10.1016/j.pnpbp.2006.02.008 CrossRefPubMed

44.

Ekholm B, Ekholm A, Adolfsson R, Vares M, Osby U, Sedvall GC, Jonsson EG (2005) Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry 59(6):457–464. doi:10.1080/08039480500360906 CrossRefPubMed

45.

Vares M, Ekholm A, Sedvall GC, Hall H, Jonsson EG (2006) Characterization of patients with schizophrenia and related psychoses: evaluation of different diagnostic procedures. Psychopathology 39(6):286–295. doi:10.1159/000095733 CrossRefPubMed

46.

Andreasen NC (1983) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa city, IA, USA

47.

Andreasen NC (1984) Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City, IA, USA

48.

Wechsler D (1981) Manual for the wechsler adult intelligence scale—revised. The Psychological Corporation, New York

49.

Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67(3):255–262. doi:10.1016/j.biopsych.2009.08.040 CrossRefPubMed

50.

Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686–693. doi:10.1176/appi.ajp.2009.09060802 CrossRefPubMed

51.

Fischl B (2012) FreeSurfer. Neuroimage 62(2):774–781. doi:10.1016/j.neuroimage.2012.01.021 CrossRefPubMedPubMedCentral

52.

Hartberg CB, Jorgensen KN, Haukvik UK, Westlye LT, Melle I, Andreassen OA, Agartz I (2015) Lithium treatment and hippocampal subfields and amygdala volumes in bipolar disorder. Bipolar Disord 17(5):496–506. doi:10.1111/bdi.12295 CrossRefPubMed

53.

Hajek T, Cullis J, Novak T, Kopecek M, Hoschl C, Blagdon R, O’Donovan C, Bauer M, Young LT, Macqueen G, Alda M (2012) Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord 14(3):261–270. doi:10.1111/j.1399-5618.2012.01013.x CrossRefPubMedPubMedCentral

54.

Garcia GJ, Chagas MH, Silva CH, Machado-de-Sousa JP, Crippa JA, Hallak JE (2015) Structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review. Rev Bras Psiquiatr 37(1):71–79. doi:10.1590/1516-4446-2014-1387 CrossRefPubMed

55.

Hutcheson NL, Clark DG, Bolding MS, White DM, Lahti AC (2014) Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry Res 221(1):6–12. doi:10.1016/j.pscychresns.2013.10.002 CrossRefPubMed

56.

Farde L, Halldin C, Stone-Elander S, Sedvall G (1987) PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology 92(3):278–284. doi:10.1007/BF00210831 CrossRefPubMed

57.

Seeman P, Wilson A, Gmeiner P, Kapur S (2006) Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse 60(3):205–211. doi:10.1002/syn.20298 CrossRefPubMed

58.

Miller JC (1990) Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J Neurochem 54(4):1453–1455. doi:10.1111/j.1471-4159.1990.tb01983.x CrossRefPubMed

59.

Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon WA Jr, Nestler EJ (1999) Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs. Synapse 33(2):118–128. doi:10.1002/(sici)1098-2396(199908)33:2<118:aid-syn2>3.0.co;2-l CrossRefPubMed

60.

Kovacs KJ (1998) c-Fos as a transcription factor: a stressful (re)view from a functional map. Neurochem Int 33(4):287–297CrossRefPubMed

61.

Pereira A, Zhang B, Malcolm P, Sundram S (2013) Clozapine regulation of p90RSK and c-Fos signaling via the ErbB1-ERK pathway is distinct from olanzapine and haloperidol in mouse cortex and striatum. Prog Neuropsychopharmacol Biol Psychiatry 40:353–363. doi:10.1016/j.pnpbp.2012.10.025 CrossRefPubMed

62.

Lahti AC, Weiler MA, Medoff DR, Tamminga CA, Holcomb HH (2005) Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia. Psychiatry Res 139(1):19–30. doi:10.1016/j.pscychresns.2005.02.006 CrossRefPubMed

63.

Zink M, Englisch S, Schmitt A (2014) Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. Eur Arch Psychiatry Clin Neurosci 264(Suppl 1):S67–S82. doi:10.1007/s00406-014-0534-4 CrossRefPubMed

64.

Schmitt A, Zink M, Muller B, May B, Herb A, Jatzko A, Braus DF, Henn FA (2003) Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res 28(2):235–241CrossRefPubMed

65.

Schmitt A, Zink M, Petroianu G, May B, Braus DF, Henn FA (2003) Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci Lett 347(2):81–84CrossRefPubMed

66.

Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, White LE (2012) Neuroscience, 5 edn. Sinauer Associates, Sunderland, MA

67.

Rimol LM, Hartberg CB, Nesvag R, Fennema-Notestine C, Hagler DJ Jr, Pung CJ, Jennings RG, Haukvik UK, Lange E, Nakstad PH, Melle I, Andreassen OA, Dale AM, Agartz I (2010) Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol Psychiatry 68(1):41–50. doi:10.1016/j.biopsych.2010.03.036 CrossRefPubMed

68.

Khorram B, Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Goghari VM, Smith GN, Honer WG (2006) Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine. Am J Psychiatry 163(11):2005–2007. doi:10.1176/appi.ajp.163.11.2005 CrossRefPubMed

Titel: First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia
verfasst von: Kjetil N. Jørgensen
Ragnar Nesvåg
Sindre Gunleiksrud
Andrea Raballo
Erik G. Jönsson
Ingrid Agartz
Publikationsdatum: 07.11.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 5/2016
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-015-0650-9

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Neurocognitive impairment in the deficit subtype of schizophrenia

Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia

Smaller than expected cognitive deficits in schizophrenia patients from the population-representative ABC catchment cohort

Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications

Endurance training in patients with schizophrenia and healthy controls: differences and similarities

Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie